Terug naar bedrijfspagina

Nieuws over MDxHealth

13/11/2025 Mdxhealth - Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2025 (13.11.2025)

16/09/2025 Mdxhealth - Announces Closing of Exosome Diagnostics Acquisition from Bio-Techne (16.09.2025)

06/08/2025 Mdxhealth - Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne (06.08.2025)

04/07/2025 Mdxhealth - Appoints Michael Holder to Board of Directors and Announces Management Change (04.07.2025)

15/05/2025 MDxHealth - Reports Q1-2025 Results (MDxHealth rapporteert resultaten Q1-2025) (15.05.2025)

27/02/2025 Mdxhealth - Announces Fourth Quarter and Full-Year 2024 Financial Results (27.02.2025)

13/01/2025 MDxHealth - Reports Preliminary Fourth Quarter and Full Year 2024 Revenues and Issues 2025 Revenue Guidance (13.01.2025)

07/11/2024 MDxHealth - Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2024 (07.11.2024)

26/09/2024 MDxHealth - Announces Launch of Offering of Ordinary Shares (26.09.2024)

22/08/2024 MDxHealth - Reports Q2 and Half Year 2024 Results (22.08.2024)

08/07/2024 MDxHealth - Reports Preliminary Q2 and Half Year 2024 Revenues and Raises 2024 Revenue Guidance (08.07.2024)

16/05/2024 Mdxhealth - to Present at Upcoming Investor Conferences (16.05.2024)

01/05/2024 MDxHealth - Reports Q1-2024 Results and Announces Growth Capital from OrbiMed (01.05.2024)

13/03/2024 Mdxhealth - Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering (13.03.2024)

07/03/2024 Mdxhealth - Announces Fourth Quarter and Full-Year 2023 Financial Results (07.03.2024)

09/01/2024 MDxHealth - Reports Preliminary Fourth Quarter and Full Year 2023 Revenues and Issues 2024 Revenue Guidance (09.01.2024)

18/12/2023 MDxHealth - Announces Completion of Transition to Single Listing on Nasdaq (18.12.2023)

27/11/2023 MDxHealth - Announces Completion of Mandatory ADS Exchange and Commencement of Transition Period to Single Listing on Nasdaq (27.11.2023)

09/11/2023 MDxHealth - Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2023 (09.11.2023)

06/11/2023 MDxHealth - Announces the Approval by its Shareholders of the Proposed Transition to a Sole Listing of Shares on Nasdaq, and Details of the Share Consolidation (06.11.2023)